Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.80), $0.49 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $138.2 million versus the consensus estimate of $103.57 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $435-450 million, versus the consensus of $434.9 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.